Rapid Generation of Human Therapuetic Antibodies Against Influenza

Information

  • Research Project
  • 7480790
  • ApplicationId
    7480790
  • Core Project Number
    R43AI078563
  • Full Project Number
    1R43AI078563-01
  • Serial Number
    78563
  • FOA Number
    PA-07-81
  • Sub Project Id
  • Project Start Date
    8/15/2008 - 16 years ago
  • Project End Date
    7/31/2010 - 14 years ago
  • Program Officer Name
    COLOMBINI-HATCH, SANDRA
  • Budget Start Date
    8/15/2008 - 16 years ago
  • Budget End Date
    7/31/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/8/2008 - 16 years ago

Rapid Generation of Human Therapuetic Antibodies Against Influenza

[unreadable] DESCRIPTION (provided by applicant): Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from mouse bone marrow stem cells, fetal cord blood and adult bone marrow stem cells. Phase I of this project includes testing existing mouse antibodies against Influenza for their ability to neutralize pathogenic strains of Influenza and adapting this technology to generate human antibodies against Influenza in a mouse model using human adult stem cells. Phase II of the project will involve optimizing large-scale production and testing of human anti-influenza antibodies. PUBLIC HEALTH RELEVANCE: This project seeks to optimize a novel method to rapidly generate human therapeutic antibodies against the Influenza virus in a mouse model using human adult stem cell lines. Once this method has been validated for Influenza, the long-term goal to benefit public health will be to use this system to generate antibodies for clinical applications in a variety of global health issues including, but not limited to, HIV-1, tuberculosis and malaria. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    180667
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:180667\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TAIGA BIOTECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    783743938
  • Organization City
    AURORA
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    800457336
  • Organization District
    UNITED STATES